First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

FDA approves third insulin biosimilar Merilog to ease U.S. supply shortage FDAs latest insulin biosimilar approval aims to mitigate ongoing supply challenges in the U.S.

Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

Mariposa California's original daily updated online newspaper is the premier site for news and information on Yosemite, ...